Long-Acting Injectable Program Implementation Insights From Genoa Healthcare® Pharmacy

Listen

0:00 / 0:00

This educational resource was sponsored by Johnson & Johnson.

Part 2 of this educational resource provides insights for institutions seeking to implement a pharmacist-led long-acting injectable administration program for schizophrenia.

Articles in this issue

5 months ago

Article

Optimizing Long-Acting Injectable Administration for Patients Living With Schizophrenia

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Latest CME

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Long-Acting Injectable Program Implementation Insights From Genoa Healthcare® Pharmacy

Articles in this issue

Newsletter

Latest CME

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”

Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP

Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial

Exploring Identity, Appearance Experiences Among Patients With Alopecia